NCC Group PLCShs Aktie 1902753 / GB00B01QGK86
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
28.10.2025 14:21:55
|
Form 8.3 - The Vanguard Group, Inc.: NCC Group plc
|
The Vanguard Group, Inc. ( )
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors’ and other employee options)
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
(b) Cash-settled derivative transactions
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
(ii) Exercise
(d) Other dealings (including subscribing for new securities)
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
(b) Agreements, arrangements or understandings relating to options or derivatives
(c) Attachments
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.
*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.
The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Category Code: | RET - NCC Group plc |
| TIDM: | |
| LEI Code: | 5493002789CX3L0CJP65 |
| Sequence No.: | 406472 |
| EQS News ID: | 2219892 |
| End of Announcement | EQS News Service |
|
|
Nachrichten zu NCC Group PLCShs
|
28.10.25 |
Form 8.3 - The Vanguard Group, Inc.: NCC Group plc (EQS Group) | |
|
27.10.25 |
Form 8.3 - The Vanguard Group, Inc.: NCC Group plc (EQS Group) | |
|
24.10.25 |
Form 8.3 - The Vanguard Group, Inc.: NCC Group plc (EQS Group) | |
|
23.10.25 |
Form 8.3 - The Vanguard Group, Inc.: NCC Group plc (EQS Group) | |
|
22.10.25 |
Form 8.3 - The Vanguard Group, Inc.: NCC Group plc (EQS Group) | |
|
21.10.25 |
Form 8.3 - The Vanguard Group, Inc.: NCC Group PLC (EQS Group) | |
|
17.10.25 |
Form 8.3 - The Vanguard Group, Inc.: NCC Group plc (EQS Group) | |
|
16.10.25 |
Form 8.3 - The Vanguard Group, Inc.: NCC Group plc (EQS Group) |
Etienne Jornod (OM Pharma): Führung, Erfolg & Pharma-Strategie- zu Gast im BX Morningcall
Im BX Morning Call spricht die Schweizer Unternehmer-Ikone Etienne Jornod (OM Pharma) mit François Bloch und Olivia Hähnel (BX Swiss) über Führung, Wachstum, Kooperationen, seine Zeit bei der NZZ und darüber, warum Zuhören der wichtigste Leadership-Skill ist.
Die perfekte Folge für alle, die sich für Pharmastrategien, Galenica/Vifor und Unternehmertum interessieren.
🎯 Themen im Interview mit Etienne Jornod (OM Pharma)
– Antrieb und Führungsphilosophie eines Unternehmers
– Erfolgsweg von Galenica – Lehren aus Jahrzehnten Führung
– Frauenquote, Teamkultur und Leadership bei OM Pharma
– Internationale Expansion: China, USA und neue Märkte
– Forschung, Druck und Verantwortung in der Pharmaindustrie
– Inspiration, Balance und persönliche Haltung zum Erfolg
– Zukunftsvisionen: Schweiz, Unternehmertum und Investments
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI und DAX eröffnen wenig bewegt -- Asiens Börsen letztlich im Plus -- Nikkei mit Allzeithoch -- Feiertag in HongkongDer heimische und der deutsche Aktienmarkt starten mit leichten Abgaben am Mittwoch. Die wichtigsten Aktienmärkte in Fernost verbuchten teilweise große Gewinne.


